Quarter 3, 2026: Clark County Disease Statistics*

Data as of 10/28/2026

Disease	2024		2025		2026		Rate (Cases per 100,000 per quarter)		Quarter Rate (% change) Comparison
	Qtr 3	YTD	Qtr 3	YTD	Qtr 3	YTD	Qtr 3 (2021-2025 average)	Qtr 3 (2026)	Change b/t current & past 5-year?
VACCINE PREVENTABLE									
COVID-19	7,385	15,624	4,848	8,858	2,083	3,452	314.01	21.20	↓X (-93.25%)
Haemophilus influenzae, invasive	10	36	2	25	7	39	0.08	.	-
Hepatitis A	4	8	0	1	1	4	.	.	-
Hepatitis B, acute	10	32	6	26	8	25	0.09	.	-
Hepatitis B, chronic	286	998	296	887	280	736	3.68	2.85	↓X (-22.55%)
Influenza	39	737	63	1,240	165	1,330	0.48	1.68	↑X (+250.00%)
Influenza-associated pediatric mortality	0	2	0	2	0	1	.	.	-
Meningococcal disease (*N. meningitidis*)	0	2	0	1	0	1	.	.	-
MPOX	2	8	2	2	18	39	0.69	0.18	↓X (-73.91%)
Mumps	0	3	1	1	1	2	.	.	-
Pertussis	7	44	18	53	8	94	0.17	.	-
RSV	40	1,967	48	2,263	40	2,508	2.83	0.41	↓X (-85.51%)
SEXUALLY TRANSMITTED									
Chlamydia	3,181	9,668	3,136	9,111	3,340	9,450	42.35	33.99	↓X (-19.74%)
Gonorrhea	1,362	4,035	1,260	3,748	1,463	3,783	19.63	14.89	↓X (-24.15%)
HIV	132	435	106	349	71	278	1.61	0.72	↓X (-55.28%)
Stage 3 HIV (AIDS)	19	101	37	137	24	114	0.49	0.24	↓X (-51.02%)
Syphilis (Early non-primary, non-secondary)	121	452	87	281	51	199	2.01	0.52	↓X (-74.13%)
Syphilis (Primary, Secondary)	107	315	48	156	37	120	1.82	0.38	↓X (-79.12%)
CONGENITAL CONDITIONS									
Hepatitis C, Perinatal Infection	1	3	1	1	0	1	.	.	-
Congenital Syphilis	10	28	8	27	5	16	70.37	.	-
ENTERICS									
Amebiasis	0	5	1	8	4	6	.	.	-
Campylobacteriosis	47	171	72	195	70	181	0.61	0.71	↑ (+16.39%)
Cryptosporidiosis	5	22	9	25	13	24	0.08	0.13	↑ (+62.50%)
Cyclosporiasis	7	11	6	9	8	14	0.04	.	-
Giardiasis	18	52	15	42	8	47	0.22	.	-
Rotavirus	17	119	33	225	29	146	0.25	0.30	↑ (+20.00%)
Salmonellosis	58	132	73	164	97	202	0.70	0.99	↑X (+41.43%)
Shiga toxin-producing *E. coli* (STEC)	34	74	27	76	24	70	0.29	0.24	↓ (-17.24%)
Shigellosis	41	116	22	60	36	76	0.33	0.37	↑ (+12.12%)
Vibriosis (Non-cholera *Vibrio* species infection)	4	13	4	10	9	17	0.04	.	-
Yersiniosis	7	30	11	42	14	38	0.07	0.14	↑ (+100.00%)
OTHER									
Coccidioidomycosis	72	196	45	189	47	186	0.67	0.48	↓ (-28.36%)
Encephalitis	0	0	1	1	0	0	.	.	-
Exposure, Chemical or Biological	0	2	0	2	0	2	.	.	-
Hepatitis C, acute	3	11	1	7	0	11	.	.	-
Hepatitis C, chronic	414	1,228	597	1,548	423	1,144	7.64	4.31	↓X (-43.59%)
Invasive Pneumococcal Disease	33	181	49	181	16	151	0.40	0.16	↓X (-60.00%)
Lead Poisoning	42	137	48	131	48	215	0.46	0.49	↑ (+6.52%)
Legionellosis	13	26	14	39	7	17	0.13	.	-
Listeriosis	1	5	1	1	1	1	.	.	-
Lyme Disease	4	8	2	5	4	9	0.05	.	-
Malaria	3	4	1	3	1	1	.	.	-
Meningitis, Aseptic	10	25	6	17	2	6	0.14	.	-
Meningitis, Bacterial Other	1	4	1	5	2	8	0.04	.	-
Meningitis, Fungal	0	3	1	1	1	2	.	.	-
Spotted Fever Rickettsiosis	1	1	0	0	0	0	.	.	-
Streptococcal Toxic Shock Syndrome (STSS)	6	28	3	21	3	23	0.05	.	-
Tuberculosis, Active	19	53	13	50	16	45	0.18	0.16	↓ (-11.11%)
West Nile Virus neuroinvasive disease	3	14	0	0	0	1	.	.	-

*Use of illness onset date in data aggregation for cases other than STD or TB (since Jan-2013) causes changes in cases reported here from previously released reports. Numbers are provisional including confirmed, probable, and suspect cases that are reportable to CDC. HIV/AIDS/TB case counts are provided on a quarterly basis. Rate suppression denoted by '.' for rates corresponding to case counts < 12.

~Diseases not reported in the past five years (aggregate data) and not reported during the current reporting period are not included in this report.

~~Confidence intervals (not shown) for the quarterly disease incidence rates provided a basis for an informal statistical test to determine if the current quarterly rates changed significantly from those of the previous 5-year aggregated rates. Green text represents rates that decreased significantly, whereas red text represents rates that increased significantly. Statistically significant changes are indicated by 'X.'